Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
暂无分享,去创建一个
G. Mills | E. Winer | G. Hortobagyi | K. Do | V. Valero | L. Cantley | N. Lin | F. Meric-Bernstam | A. Sahin | A. González-Angulo | D. Hong | S. Piha-Paul | A. Eterovic | L. Doyle | M. Chávez-MacGregor | M. Maurer | V. Abramson | Yisheng Li | J. Litton | A. Akcakanat | Huiqin Chen | Y. Xing | G. Wulf | E. Tarco | A. Mahvash | Dianna Riall
[1] N. Howlett,et al. Application of a Biphasic Mathematical Model of Cancer Cell Drug Response for Formulating Potent and Synergistic Targeted Drug Combinations to Triple Negative Breast Cancer Cells , 2020, Cancers.
[2] H. Ford,et al. Cellular Plasticity in Breast Cancer Progression and Therapy , 2020, Frontiers in Molecular Biosciences.
[3] Z. Shao,et al. Molecular subtypes and precision treatment of triple-negative breast cancer , 2020, Annals of translational medicine.
[4] D. Rauh,et al. Spotlight on AKT: Current Therapeutic Challenges. , 2020, ACS medicinal chemistry letters.
[5] S. Mok,et al. Pathogenesis and Clinical Management of Uterine Serous Carcinoma , 2020, Cancers.
[6] Yeon-Hee Park,et al. AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. , 2018 .
[7] Prabhjot S. Mundi,et al. Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial , 2018, Clinical and Translational Oncology.
[8] G. Mills,et al. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors , 2017, Clinical Cancer Research.
[9] M. Espié,et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. , 2017, The Lancet. Oncology.
[10] Zachary L. Skidmore,et al. A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer , 2017, Clinical Cancer Research.
[11] B. Taylor,et al. AKT Inhibition in Solid Tumors With AKT1 Mutations. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] P. Philip,et al. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial , 2017, JAMA oncology.
[13] K. Do,et al. A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Michael L. Wang,et al. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma , 2014, British journal of haematology.
[15] P. Munster,et al. A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies , 2015, Clinical Cancer Research.
[16] Funda Meric-Bernstam,et al. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Berry,et al. Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial. , 2015 .
[18] G. Mills,et al. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. , 2015, Journal of the National Cancer Institute.
[19] Yuan Qi,et al. Clinical actionability enhanced through deep targeted sequencing of solid tumors. , 2015, Clinical chemistry.
[20] Martin O. Leach,et al. Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers , 2014, Clinical Cancer Research.
[21] G. Mills,et al. Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer , 2014, Clinical Cancer Research.
[22] S. Chandarlapaty,et al. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors , 2013, Breast Cancer Research.
[23] G. Mills,et al. Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer , 2012, Clinical Cancer Research.
[24] David Olmos,et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] G. Mills,et al. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. , 2009, Cancer research.
[26] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[27] G. Mills,et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.
[28] M. Ringnér,et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.
[29] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[30] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[31] Teri A. Crosby,et al. How to Detect and Handle Outliers , 1993 .